Patents by Inventor Michael L. Moore

Michael L. Moore has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of producing vasodilation or antioxytocic activity
    Patent number: 4684621
    Abstract: Certain vasopressin-like peptides, which have an acyclic unit at position 1 and which have an .omega.-amino- or guanidinoalkyl substituent attached to the cysteine in the 6-position of the ring, have V.sub.1 -vasopressin and oxytocin antagonist activity. A species of this series of new compounds is [1-desaminopenicillamine-2-(O-ethyl-D-tyrosine)-8-(1,4-diaminobutane)-9-de sglycinamide]-vasopressin.
    Type: Grant
    Filed: April 16, 1986
    Date of Patent: August 4, 1987
    Assignee: SmithKline Beckman Corporation
    Inventors: James F. Callahan, William F. Huffman, Michael L. Moore, Nelson C. Yim
  • Polypeptide intermediates
    Patent number: 4658015
    Abstract: Certain vasopressin-like peptides, which have an acyclic unit at position 1 and which have an .omega.-amino- or guanidinoalkyl substituent attached to the cysteine in the 6-position of the ring, have V.sub.1 -vasopressin and oxytocin antagonist activity. A species of this series of new compounds is [1-desaminopenicillamine-2-(O-ethyl-D-tyrosine)-8-(1,4-diaminobutane)-9-de sglycinamide]-vasopressin.
    Type: Grant
    Filed: April 16, 1986
    Date of Patent: April 14, 1987
    Assignee: SmithKline Beckman Corporation
    Inventors: James F. Callahan, William F. Huffman, Michael L. Moore, Nelson C. Yim
  • Aromatic basic-tailed vasopressin antagonists
    Patent number: 4624943
    Abstract: Certain new vasopressin-like peptides which have structures characterized by having a bisaminoalkylbenzene present in the vasopressin tail at the 7- or 8-position retain vasopressin antagonist activity. A species of the invention is [1-.beta.-mercapto-.beta.,.beta.-cyclopentamethylenepropionic acid)-2-(O-ethyl)-D-tyrosine-4-valine-8-1',4'-bis(aminomethyl)benzene-9-de sglycinamide]-vasopressin.
    Type: Grant
    Filed: March 20, 1985
    Date of Patent: November 25, 1986
    Assignee: SmithKline Beckman Corporation
    Inventors: James F. Callahan, Michael L. Moore, Nelson C. Yim
  • Basic V.sub.1 -vasopressin antagonists
    Patent number: 4604378
    Abstract: Certain vasopressin-like peptides, which have an acyclic unit at position 1 and which have an .omega.-amino- or guanidinoalkyl substituent attached to the cysteine in the 6-position of the ring, have V.sub.1 -vasopressin and oxytocin antagonist activity. A species of this series of new compounds is [1-desaminopenicillamine-2-(O-ethyl-D-tyrosine)-8-(1,4-diaminobutane)-9-de sglycinamide]-vasopressin.
    Type: Grant
    Filed: November 21, 1984
    Date of Patent: August 5, 1986
    Assignee: SmithKline Beckman Corporation
    Inventors: James F. Callahan, William F. Huffman, Michael L. Moore, Nelson C. Yim
  • Intermediates for preparing octapeptide vasopressin antagonists
    Patent number: 4587045
    Abstract: Certain octapeptides, which have structures characterized by being a six unit cyclic peptide ring with a dipeptide tail which lacks a glycine unit at position 9, have potent vasopressin antagonist activity. The compounds here claimed are in general characterized by having an amino acid unit at position 4 which is other than valine. An important species of the group is [1-(.beta.-mercapto-.beta.,.beta.-cyclopentamethylenepropionic acid)-2-(O-ethyl-D-tyrosine)-4-.alpha.-aminobutyric acid-8-arginine-9-desglycine]vasopressin.
    Type: Grant
    Filed: May 16, 1985
    Date of Patent: May 6, 1986
    Assignee: SmithKline Beckman Corporation
    Inventors: William F. Huffman, Michael L. Moore
  • Basic heptapeptide vasopressin antagonists
    Patent number: 4543349
    Abstract: Certain cyclic vasopressin-like peptides, which have an .omega.-amino- or guanidinoalkyl substituent attached to the cysteine in the 6-position of the ring, have vasopressin antagonist activity. A species of this series of new compounds is [1-(.beta.-mercapto-.beta.,.beta.-cyclopentamethylenepropionic acid)-2-(O-ethyl-D-tyrosine)-4-valine-8-(1,5-diaminopentane)-8-desarginine -9-desglycinamide]-vasopressin.
    Type: Grant
    Filed: August 28, 1984
    Date of Patent: September 24, 1985
    Assignee: SmithKline Beckman Corporation
    Inventors: James F. Callahan, Michael L. Moore, Nelson C. Yim
  • Octapeptide vasopressin antagonists
    Patent number: 4542124
    Abstract: Certain octapeptides, which have structures characterized by being a six unit cyclic peptide ring with a dipeptide tail which lacks a glycine unit at position 9, have potent vasopressin antagonist activity. The compounds here claimed are in general characterized by having an amino acid unit at position 4 which is other than valine. An important species of the group is [1-(.beta.-mercapto-.beta.,.beta.-cyclopentamethylenepropionic acid)-2-(O-ethyl-D-tyrosine)-4-.alpha.-aminobutyric acid-8-arginine-9-desglycine]vasopressin.
    Type: Grant
    Filed: June 26, 1984
    Date of Patent: September 17, 1985
    Assignee: Smithkline Beckman Corporation
    Inventors: William F. Huffman, Michael L. Moore
  • Octapeptide vasopressin antagonists
    Patent number: 4469679
    Abstract: Certain octapeptides which have structures characterized by being a six unit cyclic peptide ring with a dipeptide tail have vasopressin antagonist activity. An important species of the group is [1-(.beta.-mercapto-.beta.,.beta.-cyclopentamethylenepropionic acid)-2-(O-ethyl-D-tyrosine)-4-valine-8-arginine-9-desglycine]vasopressin.
    Type: Grant
    Filed: February 16, 1983
    Date of Patent: September 4, 1984
    Assignee: SmithKline Beckman Corporation
    Inventors: William F. Huffman, Michael L. Moore
  • Iodinated vasopressin antagonists
    Patent number: 4469680
    Abstract: A series of vasopressin antagonists which have a 3'-iodo-tyrosine unit at position 2 are prepared by iodination of the tyrosine congeners. The compounds have antagonist activity manifested by an aquaretic effect and, also, are useful in studying various biological reactions.
    Type: Grant
    Filed: July 6, 1983
    Date of Patent: September 4, 1984
    Assignee: SmithKline Beckman Corporation
    Inventors: William F. Huffman, Michael L. Moore